Patent term extension strategies in the pharmaceutical industry

Pharmaceuticals Policy and Law

Volumn 6, Issue , 2005, Pages 109-122

  Bhat, Vasanthakumar N ^a  

^a PACE UNIVERSITY   (United States)

Author keywords

Generics; Market exclusivity; Paris convention; Patents; Pharmaceuticals

Indexed keywords

EID: 85013615191     PISSN: 13892827     EISSN: 2210495X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. BlueCross BlueShield Association, Intellectual Property Protection, Chapter 3, http:// bcbshealthissues.com/issues/drugprices/report/chpt3.vtml, July 3, 2003.
2. P. Boult, J. Perriens and F. Renaud-Thery, Patent Situation of HIV/AIDS-related Drugs in 80 Countries UNAIDS/WHO, Geneva, 2000.
3. P. Deschamps, Breathing New Life Into Old Products, Pharmaceutical Executive, August 2001, pp. 78-81.
4. Express Scripts Inc, Drug Trend 2002 Report, Express Scripts Inc., www.express-scripts.com, 2002, p. 4.
5. K.V. Grebmer, Issues in the Economics of the Pharmaceutical Industry, in: Pharmaceutical Medicine, Second Edition, D.M. Burley, J.M. Clarke and L. Lasagna, eds, Edward Arnold, London, 1993, p. 255.
6. C. Henry, Special Delivery, Chemical & Engineering News 78(38) (2003), 49-65.
7. F. Kermani and G. Findlay, Evaluating the Impact of Novel Drug Delivery Systems in PAREXEL’s Pharmaceutical R&D Statistical Sourcebook, 2002, p. 90.
8. D.H. Kreling, D.A. Mott, J.B. Wiederholt, J. Lundy and L. Levitt, Prescription Drug Trends: A Chartbook Update, The Kaiser Family Foundation, 2001, www.kff.org.
9. NIHCM Foundation, Changing Patterns of Pharmaceutical Innovation, NIHCM Foundation, Washington, DC. 2002.
10. PAREXEL (2002) PAREXEL’s Pharmaceutical R&D Statistical Sourcebook, 2002, p. 91 quoting Datamonitor, Shielding Patented Drugs from the Generic Storm: New Formulations May Be Best Option, 2001.
11. W.G. Park and D. Lippoldt, The Impact Of Trade-Related Intellectual Property Rights On Trade And Foreign Direct Investment In Developing Countries, Organisation for Economic Cooperation and Development, Paris, May 28, 2003, TD/TC/WP(2002)42/FINAL, www.oecd.org/trade.
12. A. Paz, Developing Blockbuster Portfolios, 1996, www.cpsnet.com.
13. Public Citizen, Patently Offensive: Congress Set to Extend Monopoly Patents for Cipro and Other Drugs, 2001 http://www.citizen.org/congress/reform/drug patents/pediatric/articles.cfm?ID=6435 quoting US Food and Drug Administration, The Pediatric Exclusivity Provision: Status Report to Congress, January 2001, http://www.fda.gov/cder/pediatric/reportcong01.pdf
14. Christopher-Paul Milne, The Pediatric Studies Incentive: Equal Medicines For All, Tufts Center for the Study of Drug Development, April 2001.
15. W.H. Schacht and J.R. Thomas, Patent Law and Its Application to the Pharmaceutical Industry: An Examination of the Drug Price Competition and Patent Term Restoration Act of 1984 (The Hatch-Waxman Act), Updated December 18, 2000, CRS Report RL30756.
16. B. Seyoum, The Impact of Intellectual Property Rights on Foreign Direct Investment, The Columbia Journal of World Business, Spring (1996), 50-59.
17. M. Thamer, N. Brennan and R. Semansky, A Cross-National Comparison of Orphan Drug Policies: Implications for the US Orphan Drug Act, Journal of Health Politics, Policy and Law 23(2) (1998), 265-290.
18. U.S. Congress, Closing the Gaps in Hatch-Waxman: Assuring Greater Access to Affordable Pharmaceuticals, Hearing before the Committee on Health Education, Labor, and Pensions, United State, 107th Congress, May 8, 2002, US Government Printing Office, 2002, Washington, DC, pp. 9-10.
19. U.S. Congress, Office of Technology Assessment, Pharmaceutical R&D: Costs, Risks and Rewards, OTA-H-522, US Government Printing Office, Washington, DC, 1993, 20-21.
20. U.S. Federal Trade Commission, Generic Drug Entry Prior to Patent Expiration: An FTC Study, US Federal Trade Commission, Washington, DC, 2002, p. iii.
21. U.S. Food and Drug Administration, Approved Active Moieties to Which FDAhas Granted Pediatric Exclusivity for Pediatric Studies under Section 505A of the Federal Food, Drug, and Cosmetic Act, http://www.fda.gov/cder/pediatric/exgrant.htm, July 23, 2004.
22. U.S. Food and Drug Administration, Pediatric Drug Development, http://www.fda.gov/cder/ pediatric/, June 30, 2003.
23. U.S. Food and Drug Administration, Orphan Drugs, 2004 http://www.fda.gov/cder/handbook/ orphan.htm.
24. R.Winslow and B. Martinez, Efforts to Switch Patients to Generic Prozac Advance, The Wall Street Journal (August 20, 2001), A3.
25. R. Whiting, Protecting the power of the idea, Electronic Business, February 24 (1992), 24-32.